OpenEvidence Integrates MSK Genetics Data for Oncologists Nationwide

OncoKB is now available to medical professionals throughout the United States following a partnership between Memorial Sloan Kettering Cancer Center and OpenEvidence. The collaboration embeds MSK's expert interpretations of tumor genetics directly into the OpenEvidence AI platform to widen the reach of specialized cancer data. More than 85% of oncologists at MSK already utilize OpenEvidence in their daily practice.